Abstract Titles
Skip to Late-Breaking Abstracts »
All accepted abstracts will be available in the Journal for ImmunoTherapy of Cancer (JITC).
Abstract Titles
Onsite Posters
Onsite posters will be presented in the Poster Hall at the Walter E. Washington Convention Center in Washington, D.C. All odd numbered posters will be presented on Friday, Nov. 12, 2021. Even numbered posters will be presented Saturday, Nov. 13, 2021.
ePosters
ePosters will be on display on the SITC 2021 virtual meeting platform from 7 a.m. EST on Friday, Nov. 12, 2021 until the virtual meeting platform is closed on Jan. 9, 2022.
| # | Type | Title | Authors | Category | Keywords |
|---|---|---|---|---|---|
| 628 | Poster Presentation | Real-world clinical outcomes among patients with advanced Merkel cell carcinoma treated with avelumab in academic medical centers in the United States | Shailender Bhatia, MD; Paul T. Nghiem, MD, PhD; S Phani Veeranki; Alejandro Vanegas; Kristina Lachance; Lisa Tachiki; Kevin Chiu; Emily Boller; Murtuza Bharmal, PhD, MS, BPharm | Education and Treatment Management | Checkpoint blockade;Clinical study;Epidemiology;Solid tumors |
| 629 | Poster Presentation | Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors | Priyanka V. Chablani, MD; Theodore Karrison, PhD; Walter Stadler, MD | Education and Treatment Management | Checkpoint blockade;Chemotherapy;Clinical study;Solid tumors |
| 630 | Poster Presentation | Oncologists’ perspectives on evolution of first-line immune checkpoint inhibitor maintenance therapy in management of advanced urothelial carcinoma in the US | Petros Grivas; Phani Veeranki; Kevin Chiu; Vivek Pawar; Jane Chang; Murtuza Bharmal, PhD, MS, BPharm | Education and Treatment Management | Checkpoint blockade;Chemotherapy;Clinical study;Solid tumors |
| 631 | Poster Presentation | Deep, durable response to PD-1 inhibitor monotherapy in microsatellite-stable, tumor mutational burden-high colorectal cancer | Samuel J. Schellenberg, BS; Leeseul Kim, MD; Young Kwang Chae, MD, MPH, MBA | Education and Treatment Management | Biomarkers;Checkpoint blockade;Neoantigens;Solid tumors;Tumor antigens |
| 632 | Poster Presentation | Toripalimab combined with platinum-based chemotherapy as a second-line treatment for small cell lung cancer (SCLC) with brain metastases: A case report | Jieqiong Fan; Yao Zhang; Xiaofei Mo; Jing Guo | Education and Treatment Management | Antibody;Checkpoint blockade;Solid tumors |
| 633 | Poster Presentation | Incorporating Checkpoint Inhibitors into Cancer Care: A study of the impact of digital education on clinical competence and practice patterns | Tariqa Ackbarali, MS, PhD(c); Elizabeth L. del Nido, BA; Brian I. Rini, MD; Michael J. Overman, MD; Ignacio I. Witsuba, MD | Education and Treatment Management | Biomarkers;Checkpoint blockade;Immune toxicity;Solid tumors;Tumor microenvironment |
| 635 | Poster Presentation | Online CME improves the interprofessional team’s ability to manage patients with malignant pleural mesothelioma | Michelle A. Worst, PharmD, BCOP, MBA; Emily Van Laar; Megan Whitney, DMD; Anne Tsao, MD; Hossein Borghaei, MS, DO | Education and Treatment Management | Checkpoint blockade;Chemotherapy;Epidemiology;Immune toxicity;Solid tumors;Targeted therapy;Tumor microenvironment |
| 636 | Poster Presentation | Patient-Reported Distress with Immunotherapy-Based First-Line Treatment for mNSCLC: a Real-World Evidence Study | Monica H. Bodd, BA; Susan C. Locke, PhD; Scott Antonia, MD, PhD; Jeffrey Crawford, MD; John Hartman, PhD; Kris Herring, PhD; Neal Ready, MD, PhD; Thomas E. Stinchcombe, MD; Jesse D. Troy, PhD; Chakita Williams, PhD; Steven Wolf, MS; Jeffrey M. Clarke, MD; Thomas W. LeBlanc, MD MA MHS FAAHPM FASCO | Education and Treatment Management | Chemotherapy;Clinical study;Solid tumors |
| 637 | Poster Presentation | Exploring the Impact of Immunotherapy on Cancer Patients’ Real World Experience | Helen M. Nichols, PhD; Helen M. Nichols, PhD, MSW; Elise Wu | Education and Treatment Management | Targeted therapy |
Presented By:
